Rezatapopt's 46% ORR in TP53 Y220C Ovarian Cancer: First-Mover Strength Meets Single-Arm Evidentiary Ceiling

PMV Pharma Reports Strong Interim Rezatapopt Data in Ovarian Cancer

PMV Pharmaceuticals announced updated interim data from the ovarian cancer cohort of its PYNNACLE Phase 2 pivotal trial for rezatapopt monotherapy. The data, as of May 14, 2026, showed a 46% overall response rate (ORR) among 76 evaluable patients with platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation. The median duration of response (DoR) was 10.0 months. The company also reported positive feedback from the FDA, supporting its strategy for submitting a New Drug Application (NDA) for accelerated approval in the first quarter of 2027. Rezatapopt demonstrated a favorable safety profile with mostly Grade 1 and 2 treatment-related adverse events.

• Rezatapopt monotherapy achieved a 46% overall response rate (ORR) in 76 evaluable patients with platinum-resistant/refractory ovarian cancer and a TP53 Y220C mutation. This included four confirmed complete responses and 29 confirmed partial responses, with a rapid median time to response of 1.3 months and a durable median duration of response of 10.0 months.
• The interim data highlighted rezatapopt's consistent and favorable safety profile across all cohorts, including the ovarian cancer cohort. The majority of treatment-related adverse events were Grade 1 and 2, and the discontinuation rate due to treatment-related AEs was low at 5%, indicating good tolerability for patients.
• PMV Pharma received supportive feedback from the U.S. FDA regarding its strategy for an accelerated approval New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation. The company plans to submit the NDA in the first quarter of 2027, leveraging the Phase 2 PYNNACLE trial data.

Addressing Challenges in Platinum-Resistant TP53 Y220C Ovarian Cancer

Platinum-resistant ovarian cancer harboring TP53 mutations represents one of the most therapeutically intractable settings in oncology, with median overall survival typically under one year following relapse. While data specific to the Y220C variant remain limited, the broader landscape of TP53-mutant, platinum-resistant disease is defined by overlapping resistance mechanisms and compounding clinical complexities.

• Chemoresistance and Incomplete Mechanistic Understanding: High-grade serous ovarian carcinoma with TP53 mutations typically relapses within six months of first-line therapy due to chemoresistance. Critically, the molecular mechanisms underlying acquired drug resistance have not been fully elucidated across different TP53 mutation types, limiting rational therapeutic design.

• ABCB1-Mediated and Stemness-Driven Resistance: Acquired carboplatin resistance in p53-null contexts drives accumulation of cells in the G2/M phase, a subpopulation characterized by elevated stemness marker expression, high proliferative capacity, and attenuated DNA repair function — all of which contribute to sustained chemoresistance. The extent to which this mechanism applies varies by specific TP53 mutation type.

• Sustained DNA Damage Response Signaling: In cisplatin-resistant ovarian cancer cells, the DDUP microprotein maintains RAD18/RAD51C and RAD18/PCNA complexes at DNA damage sites, enabling dual-pathway resistance through both homologous recombination and post-replication repair mechanisms — effectively circumventing cytotoxic cell death.

• AKT Pathway-Mediated Platinum Evasion: Platinum exposure activates a prosurvival AKT-dependent DNA damage response in clinically resistant cells, wherein AKT translocates to the nucleus and is phosphorylated on S473 by DNA-PK, suppressing cisplatin-mediated apoptosis. Although DNA-PK or AKT inhibition can restore platinum sensitivity in preclinical models, this strategy remains investigational.

• Tolerability Constraints with Combination Regimens: The phase II evaluation of adavosertib combined with carboplatin and paclitaxel in TP53-mutated, platinum-sensitive ovarian cancer revealed a substantially elevated adverse event burden — including diarrhea (75% vs. 37% placebo), vomiting (63% vs. 27%), anemia (53% vs. 32%), and grade ≥3 events (78% vs. 65%) — highlighting that identifying optimal tolerability strategies and biomarker-defined patient populations will be essential to realizing clinical benefit.

• BRCA Status as a Confounding Variable in p53 Reactivation: BRCA2 status modulates the transcriptional effect of p53 reactivators across multiple target loci, indicating that BRCA status of TP53-missense-mutant ovarian tumors should be factored into therapeutic decision-making — adding a meaningful layer of complexity to treatment selection in this population.

• Apoptosis Pathway Evasion: Alterations in apoptotic signaling molecules represent a convergent resistance mechanism, enabling tumor cells to evade programmed cell death and further diminishing the efficacy of cytotoxic and targeted agents in the platinum-resistant setting.

Pivoting Towards a New Era in TP53-Mutated Ovarian Cancer

The latest interim data for rezatapopt marks a significant stride in the challenging landscape of platinum-resistant/refractory ovarian cancer, particularly for patients harboring the specific TP53 Y220C mutation. This patient population faces a dire prognosis with limited effective treatment options, making the reported 46% overall response rate and 10.0-month median duration of response clinically meaningful. Rezatapopt's mechanism, as a first-in-class p53 reactivator, represents a novel approach to restoring tumor suppressor function, a long-sought goal in oncology.

The positive feedback from the FDA regarding an accelerated approval pathway underscores the potential for this targeted therapy to reach patients sooner. This strategic move could position PMV Pharmaceuticals as a leader in precision oncology, validating the concept of directly targeting specific TP53 mutations. However, several considerations remain pertinent:

• While the ovarian cancer data is strong, the broader Phase 1 study indicated a lower overall response rate across various tumor types, suggesting that efficacy might be highly specific to certain indications or patient subsets.

• The Phase 1 data also highlighted anemia as a notable Grade 3 or higher adverse event, which, despite the generally favorable safety profile reported, will require careful management in clinical practice.

• The current data is derived from heavily pretreated patients, meaning the drug's role and efficacy in earlier lines of therapy or in less refractory settings are yet to be determined.

Ultimately, rezatapopt's progress offers a beacon of hope for a difficult-to-treat cancer, demonstrating the power of biomarker-driven drug development. Its potential accelerated approval could reshape treatment paradigms for TP53 Y220C-mutated cancers, paving the way for further exploration of p53 reactivation across oncology.